AstraZeneca Wainua Trial Failure|20bn Wiped as ATTR Heart Drug Misses Primary Endpoint

The Drug That Was Meant to Be a Slam Dunk

AstraZeneca shares fell 8.8% on Thursday after its gene-silencing drug Wainua failed the CARDIO-TTRansform Phase 3 trial in transthyretin amyloid cardiomyopathy — erasing more than £20 billion from the company's market value in a single session.

The paradox is immediate: Jefferies analysts, hours after the data dropped, called the market reaction an "over-reaction" — citing that peak sales estimates are "only mildly impacted" and that AZ "remains a premium growth company" on track for $80 billion in 2030 revenues.

Yet ATTR-CM is not a footnote in AZ's pipeline. The ATTR-CM patient population is six to ten times larger than the nerve-damage ATTR-PN form Wainua already treats — 300,000 to 500,000 patients globally versus fewer than 50,000 in ATTR-PN.

Before today, analysts projected Wainua peak sales of $6.5 billion. The Financial Times reported those forecasts have now been cut to around $4 billion. That is a $2.5 billion annual revenue gap the 2030 model must now find elsewhere.

The question is whether Jefferies is right that the remaining pipeline absorbs that gap, or whether the failure signals something deeper about AZ's trial design credibility in a market where getting ATTR-CM right was always the key test.

The Stabiliser Paradox: Why the Trial Was Set Up to Fail

The CARDIO-TTRansform study enrolled 1,432 patients across 20 countries, testing Wainua as an add-on therapy against a placebo — both groups on standard care, which in most cases included a stabiliser drug like Pfizer's Vyndamax.

That design choice is the key fact the surface reading misses. At baseline, 57% of patients in each arm were already on stabilisers, and 24% added them during the trial. By the time Wainua was trying to show its value, the majority of patients had already received the drug class most likely to reduce their cardiovascular events.

William Blair analyst Myles Minter said the failure was surprising given the "well-documented combination use benefit of stabilizers and silencers" in Alnylam's rival HELIOS-B trial. The expectation was that combining two mechanism classes — silencing and stabilising — would outperform stabilisers alone.

It did not. And there is a buried assumption in that design: AZ assumed that the ATTR-CM treatment landscape would remain early-stage enough that adding Wainua on top of stabilisers would still show incremental benefit. Instead, the trial ran into a standard of care that had itself become highly effective, compressing the room for Wainua to demonstrate separation from placebo.

A prespecified subgroup of patients on Wainua as a monotherapy — without a background stabiliser — did show nominally significant improvement. That single data point matters enormously. It means the drug may work; the trial tested the wrong combination.

Ionis CEO Brett Monia said the results "have the potential to guide the treatment landscape" — an acknowledgement that the science is not dead, but that the commercial ATTR-CM plan built on add-on positioning almost certainly is.

Capital Rotation: Who Gained What AZ Lost

The market did not treat the CARDIO-TTRansform failure as a setback for the ATTR-CM category — it treated it as a redistribution of market share.

Alnylam Pharmaceuticals, whose rival silencer Amvuttra won its own HELIOS-B trial against placebo in a population where only about a third of patients were on background stabilisers, rose 10% on Thursday. BridgeBio Pharma, maker of stabiliser Attruby, climbed 15%.

Those moves are not coincidental. They are capital flowing out of AZ and Ionis and into the two companies whose ATTR-CM drugs are now positioned as the standard of care that Wainua failed to beat.

Pfizer's Vyndamax, already the market leader at $6.4 billion in annual sales, also benefits: the trial failure validates the stabiliser class as effective enough to block an add-on silencer from showing incremental benefit.

For Ionis, the damage is sharper. The company depends on Wainua royalty revenue, earning $49 million from ATTR-PN sales last year. Its stock fell more than 17% on the day. Unlike AZ, Ionis does not have an $80 billion revenue target absorbing the blow; Wainua in ATTR-CM was a material part of the commercial story.

The rotation confirms that the market is not re-rating the ATTR-CM opportunity downward. It is re-ranking which companies own it.

The $80bn Target and the Two Tests That Now Define AZ's Case

Jefferies is not wrong that Wainua's ATTR-CM loss has "limited impact" on AZ's 2030 model in isolation. AZ generated $58.7 billion in revenue last year across oncology, cardiovascular, respiratory, and rare disease. The $2.5 billion gap from the revised Wainua peak is material but not fatal for a company with Enhertu — whose DESTINY-Breast05 trial already earned Breakthrough Therapy Designation from the FDA — and pipeline assets in breast cancer, lung cancer, and lupus.

The credibility question is different. Jefferies itself flagged a potential "credibility loss" because AZ is known for its "exceptionally good trial design ability." CARDIO-TTRansform failed on a design assumption — that add-on efficacy would survive in a stabiliser-saturated population — that Alnylam's prior trial had already signalled was risky.

That is the counter-evidence that holders and watchers need to weigh: if AZ's trial design team missed the stabiliser saturation signal that competitor data had already surfaced, what does that imply for the two remaining high-stakes 2026 readouts — SERENA-4 (camizestrant in HR-positive breast cancer) and AVANZAR (datopotamab deruxtecan in lung cancer)?

Those two trials carry genuine blockbuster potential. SERENA-4's all-comer HR-positive population and AVANZAR's TROP2-targeting design were each cited by AZ as among the three pivotal 2026 readouts, alongside CARDIO-TTRansform. One of the three has now failed.

The full CARDIO-TTRansform dataset, including the monotherapy subgroup analysis, will be presented at the European Society of Cardiology congress in Munich in August. That presentation is the nearest discriminating event: if the monotherapy subgroup data is strong enough to support a repositioned ATTR-CM trial design, the pipeline damage is contained. If the data shows Wainua's silencing effect was itself insufficient — not just buried by stabilisers — then the add-on failure reflects a drug limitation, not merely a trial design error, and the recovery path narrows.

For holders, the position survives if SERENA-4 and AVANZAR read out positively over the next two quarters. For those watching from the sideline, the ESC August data is the first checkpoint: strong monotherapy subgroup results reopen ATTR-CM optionality; weak results confirm the commercial write-off.

The £20bn move was not purely about Wainua. It was about whether one missed assumption in trial design is a one-off or a pattern.